Prognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients

Fausto Petrelli, G. Viale, M. Cabiddu, S. Barni

Research output: Contribution to journalArticle

Abstract

A proliferative marker, expressed as the percentage of cells in a cell cycle, has been developed and used as a discriminant of more aggressive malignant phenotypes in early breast cancer (BC). The marker is usually expressed by the immunohistochemical staining of the cell cycle antigen Ki-67. It has not, however, yet been definitely evaluated, due to methodological concerns, which specific Ki-67 cut-off provide the strongest prognostic information in resected BC. We conducted a meta-analysis to explore the prognostic value of different cut-off levels of Ki-67 in terms of overall survival (OS) and disease-free survival (DFS) in early BC. The databases of PubMed, the ISI Web of Science, EMBASE, SCOPUS, the Cochrane Central Register of Controlled Trials, and CINHAL were used to identify the relevant literature. Data from studies reporting a hazard ratio (HR) and a 95 % confidence interval (CI) calculated as a multivariate analysis were pooled in a meta-analysis, with metaregression used to test for trends in predefined subgroups. All the statistical tests were 2-sided. Forty-one studies encompassing 64,196 BC patients were included in the analysis. Overall, n = 25 studies were available for the OS analysis. The pooled HR for high versus low Ki-67 was 1.57 (95 % CI 1.33–1.87, P 25 % is associated with a greater risk of death compared with lower expression rates.

Original languageEnglish
Pages (from-to)477-491
Number of pages15
JournalBreast Cancer Research and Treatment
Volume153
Issue number3
DOIs
Publication statusPublished - Sep 4 2015

Fingerprint

Meta-Analysis
Breast Neoplasms
Cell Cycle
Confidence Intervals
Ki-67 Antigen
Survival Analysis
PubMed
Disease-Free Survival
Research Design
Multivariate Analysis
Databases
Staining and Labeling
Phenotype
Survival

Keywords

  • Breast cancer
  • Ki-67
  • Meta-analysis
  • Prognostic factor
  • Proliferative marker

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Prognostic value of different cut-off levels of Ki-67 in breast cancer : a systematic review and meta-analysis of 64,196 patients. / Petrelli, Fausto; Viale, G.; Cabiddu, M.; Barni, S.

In: Breast Cancer Research and Treatment, Vol. 153, No. 3, 04.09.2015, p. 477-491.

Research output: Contribution to journalArticle

@article{0c2925829c3b42e49eb507f2aa9a3980,
title = "Prognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients",
abstract = "A proliferative marker, expressed as the percentage of cells in a cell cycle, has been developed and used as a discriminant of more aggressive malignant phenotypes in early breast cancer (BC). The marker is usually expressed by the immunohistochemical staining of the cell cycle antigen Ki-67. It has not, however, yet been definitely evaluated, due to methodological concerns, which specific Ki-67 cut-off provide the strongest prognostic information in resected BC. We conducted a meta-analysis to explore the prognostic value of different cut-off levels of Ki-67 in terms of overall survival (OS) and disease-free survival (DFS) in early BC. The databases of PubMed, the ISI Web of Science, EMBASE, SCOPUS, the Cochrane Central Register of Controlled Trials, and CINHAL were used to identify the relevant literature. Data from studies reporting a hazard ratio (HR) and a 95 {\%} confidence interval (CI) calculated as a multivariate analysis were pooled in a meta-analysis, with metaregression used to test for trends in predefined subgroups. All the statistical tests were 2-sided. Forty-one studies encompassing 64,196 BC patients were included in the analysis. Overall, n = 25 studies were available for the OS analysis. The pooled HR for high versus low Ki-67 was 1.57 (95 {\%} CI 1.33–1.87, P 25 {\%} is associated with a greater risk of death compared with lower expression rates.",
keywords = "Breast cancer, Ki-67, Meta-analysis, Prognostic factor, Proliferative marker",
author = "Fausto Petrelli and G. Viale and M. Cabiddu and S. Barni",
year = "2015",
month = "9",
day = "4",
doi = "10.1007/s10549-015-3559-0",
language = "English",
volume = "153",
pages = "477--491",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York LLC",
number = "3",

}

TY - JOUR

T1 - Prognostic value of different cut-off levels of Ki-67 in breast cancer

T2 - a systematic review and meta-analysis of 64,196 patients

AU - Petrelli, Fausto

AU - Viale, G.

AU - Cabiddu, M.

AU - Barni, S.

PY - 2015/9/4

Y1 - 2015/9/4

N2 - A proliferative marker, expressed as the percentage of cells in a cell cycle, has been developed and used as a discriminant of more aggressive malignant phenotypes in early breast cancer (BC). The marker is usually expressed by the immunohistochemical staining of the cell cycle antigen Ki-67. It has not, however, yet been definitely evaluated, due to methodological concerns, which specific Ki-67 cut-off provide the strongest prognostic information in resected BC. We conducted a meta-analysis to explore the prognostic value of different cut-off levels of Ki-67 in terms of overall survival (OS) and disease-free survival (DFS) in early BC. The databases of PubMed, the ISI Web of Science, EMBASE, SCOPUS, the Cochrane Central Register of Controlled Trials, and CINHAL were used to identify the relevant literature. Data from studies reporting a hazard ratio (HR) and a 95 % confidence interval (CI) calculated as a multivariate analysis were pooled in a meta-analysis, with metaregression used to test for trends in predefined subgroups. All the statistical tests were 2-sided. Forty-one studies encompassing 64,196 BC patients were included in the analysis. Overall, n = 25 studies were available for the OS analysis. The pooled HR for high versus low Ki-67 was 1.57 (95 % CI 1.33–1.87, P 25 % is associated with a greater risk of death compared with lower expression rates.

AB - A proliferative marker, expressed as the percentage of cells in a cell cycle, has been developed and used as a discriminant of more aggressive malignant phenotypes in early breast cancer (BC). The marker is usually expressed by the immunohistochemical staining of the cell cycle antigen Ki-67. It has not, however, yet been definitely evaluated, due to methodological concerns, which specific Ki-67 cut-off provide the strongest prognostic information in resected BC. We conducted a meta-analysis to explore the prognostic value of different cut-off levels of Ki-67 in terms of overall survival (OS) and disease-free survival (DFS) in early BC. The databases of PubMed, the ISI Web of Science, EMBASE, SCOPUS, the Cochrane Central Register of Controlled Trials, and CINHAL were used to identify the relevant literature. Data from studies reporting a hazard ratio (HR) and a 95 % confidence interval (CI) calculated as a multivariate analysis were pooled in a meta-analysis, with metaregression used to test for trends in predefined subgroups. All the statistical tests were 2-sided. Forty-one studies encompassing 64,196 BC patients were included in the analysis. Overall, n = 25 studies were available for the OS analysis. The pooled HR for high versus low Ki-67 was 1.57 (95 % CI 1.33–1.87, P 25 % is associated with a greater risk of death compared with lower expression rates.

KW - Breast cancer

KW - Ki-67

KW - Meta-analysis

KW - Prognostic factor

KW - Proliferative marker

UR - http://www.scopus.com/inward/record.url?scp=84942990308&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942990308&partnerID=8YFLogxK

U2 - 10.1007/s10549-015-3559-0

DO - 10.1007/s10549-015-3559-0

M3 - Article

C2 - 26341751

AN - SCOPUS:84942990308

VL - 153

SP - 477

EP - 491

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 3

ER -